
CryoPort (CYRX) Stock Forecast & Price Target
CryoPort (CYRX) Analyst Ratings
Bulls say
CryoPort Inc. has demonstrated a robust financial performance, achieving a total revenue of $44 million, which reflects a 15% year-over-year growth in constant currency (CC), slightly improving from the previous quarter's growth of 14% CC. The company is experiencing a rise in gene therapy programs across all stages, fueled by advancements in oncology and rare disease therapies, contributing to an upward trend in the number of approved therapies and those in development. Overall, the growth in commercial revenue and clinical trial activity, supported by increasing market acceptance of cell and gene therapies, positions CryoPort favorably for continued expansion in the life sciences sector.
Bears say
CryoPort Inc. is experiencing a decline in funding for startups within its sector, which may hinder future growth opportunities, particularly as revenue from both the Life Sciences Services and Life Sciences Products segments shows signs of slowing growth. Although Life Sciences Services reported a year-over-year revenue increase of 16% to $24 million, this growth rate has decreased from 21% in the prior quarter, and adjusted EBITDA margin remains negative at (1.5%), underperforming consensus expectations. Furthermore, a bear case scenario suggests that anticipated slowdowns in cell and gene therapy approvals, coupled with reduced demand for MVE freezers and lowered earnings expectations for 2026, indicate significant challenges to the company's revenue potential and profitability moving forward.
This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.
CryoPort (CYRX) Analyst Forecast & Price Prediction
Start investing in CryoPort (CYRX)
Order type
Buy in
Order amount
Est. shares
0 shares